Peripheral Neuropathy Management

Introduction

Peripheral neuropathy is a common complication of diabetes, affecting up to 50% of patients, with a significant impact on quality of life and increased risk of foot ulcers and amputations 1, 2, 3

First-line pharmacological treatment for peripheral neuropathy includes duloxetine, pregabalin, or gabapentin, with duloxetine being the preferred option due to its FDA approval and superior side effect profile, as recommended by the American Diabetes Association 4
Pregabalin (150-600mg/day) has predictable pharmacokinetics and no drug interactions, but may cause weight gain, edema, and dizziness 4
Tricyclic antidepressants (amitriptyline, nortriptyline) are contraindicated in patients with glaucoma, cardiovascular disease, or orthostatic hypotension, and should be started at low doses (10-25mg) and titrated slowly 4
Gabapentinoids, serotonin-norepinephrine reuptake inhibitors, or tricyclic antidepressants are recommended for first-line pain control, with second-line options including tricyclic antidepressants and sodium channel blockers, as recommended by the American Diabetes Association 5, 6

Topical treatments, such as capsaicin cream (0.075%) applied 3-4 times daily, may be effective for localized symptoms 4
Topical baclofen-amitriptyline-ketamine gel may be considered for selected patients with localized symptoms 7
Combination therapy with an opioid agonist may be considered when single-agent therapy is inadequate, but opioids should be used cautiously due to addiction risk, as stated by the Centers for Disease Control and Prevention and the American Diabetes Association 4, 2, 8, 9, 10

Optimizing glucose control can help prevent progression of diabetic neuropathy, with Grade A evidence for type 1 diabetes and Grade C evidence for type 2 diabetes, as recommended by the American Diabetes Association 11, 5
Appropriate footwear and offloading devices are recommended to prevent foot complications, with a multidisciplinary approach for individuals with high-risk feet, as recommended by the American Diabetes Association and the International Working Group on the Diabetic Foot (IWGDF) 11, 12, 6, 8
Exercise therapy may provide benefit, but requires further study 13
Annual comprehensive foot examinations are recommended, including small-fiber function, large-fiber function, and protective sensation testing, as recommended by the American Diabetes Association 5, 3

Acetyl-L-carnitine should not be used for prevention or treatment of chemotherapy-induced peripheral neuropathy, as evidence shows it may worsen symptoms 13
Alpha-lipoic acid has shown poor tolerability and limited efficacy in clinical trials 13
Calcium and magnesium infusions are not recommended for oxaliplatin-induced neuropathy 13

Foot care recommendations include wearing loose-fitting shoes and cotton socks, keeping feet uncovered in bed, walking to help blood circulation, and soaking feet in cold water and massaging for temporary relief, as suggested by the European Hematology Association and the American Diabetes Association 14, 9, 8, 11
Lifestyle modifications, including weight loss programs, avoiding tight clothing and belts, and avoiding prolonged standing or sitting positions, are critical in managing meralgia paresthetica, especially in patients with a high BMI, as recommended by the American Diabetes Association 9

The International Working Group on the Diabetic Foot (IWGDF) risk classification system can be used to guide follow-up and monitoring, with categories including:
Category Risk Level Examination Frequency
0 Very low risk
1 Low risk every 6-12 months
2 Moderate risk every 3-6 months
3 High risk every 1-3 months [8, 15, 4]
Monitoring for medication side effects, particularly in older patients, is crucial, and opioids should be avoided as they are not recommended as first-line therapy for neuropathic pain due to addiction risk, as stated by the Centers for Disease Control and Prevention and the American Diabetes Association 2, 8, 9, 10

Referral to a neurologist or pain specialist is recommended when adequate pain management is not achieved, and peripheral nerve blocks are considered a medically necessary option for patients with diabetic neuropathy who have failed first-line pharmacological therapy, as recommended by the American Diabetes Association 5, 16, 17